Incannex Healthcare Limited
IXHLNASDAQHealthcare● Active
$3.40
+$0.48(+16.44%)
Market Cap$39048170
P/E Ratio—
52W High$49.8
52W Low$2.49
Incannex Healthcare Limited (IXHL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IXHL · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.35
Est. -$0.60 · +41.7%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
IXHL reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Oct 5, 2026 | -$0.60 | — | — | — | — | — |
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.60 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.60 | -$0.35 | +41.7% | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.60 | -$0.35 | +41.7% | — | $0.00B | — |
| ▼ Q3 FY2025 | Sep 29, 2025 | -$0.29 | -$0.39 | -34.5% | $0.00B | $0.00B | -66.7% |
| — Q2 FY2025 | May 15, 2025 | — | -$1.01 | — | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.46 | -$0.24 | +47.8% | $0.00B | $0.00B | -93.8% |
| — Q4 FY2024 | Nov 14, 2024 | — | -$1.36 | — | $0.00B | — | — |
Q4 FY2026
Oct 5, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.35
EPS Est.
-$0.60
EPS Surpr.
+41.7%
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.35
EPS Est.
-$0.60
EPS Surpr.
+41.7%
Revenue
—
Q3 FY2025
Sep 29, 2025Miss
EPS Actual
-$0.39
EPS Est.
-$0.29
EPS Surpr.
-34.5%
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
-$1.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.46
EPS Surpr.
+47.8%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024
EPS Actual
-$1.36
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $1.20 | $1.20 | $1.20 | 1 |
| Q1 FY2027 | $0.30 | $0.30 | $0.30 | 1 |
| Q4 FY2026 | $0.30 | $0.30 | $0.30 | 1 |
| Q3 FY2026 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q2 FY2026 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q1 FY2026 | $-0.60 | $-0.60 | $-0.60 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +41.7% | $3.88 | $3.96 | +2.06% |
| ▲ Q2 FY2026 | May 15, 2026 | +41.7% | $3.88 | $3.96 | +2.06% |
| ▼ Q3 FY2025 | Sep 29, 2025 | -34.5% | $17.85 | $15.57 | -12.77% |
| — Q2 FY2025 | May 15, 2025 | — | $21.00 | $8.06 | -61.62% |
| ▲ Q2 FY2025 | May 15, 2025 | +47.8% | $21.00 | $8.06 | -61.62% |
| — Q4 FY2024 | Nov 14, 2024 | — | $79.50 | $70.20 | -11.70% |
| ▲ Q3 FY2024 | Sep 30, 2024 | +48.7% | $60.60 | $59.70 | -1.49% |
| — Q2 FY2024 | May 15, 2024 | — | $91.80 | $87.00 | -5.23% |
Q2 FY2026+2.06%
Report Date
May 15, 2026
EPS Beat/Miss
+41.7%
Price Before
$3.88
Price After
$3.96
Q2 FY2026+2.06%
Report Date
May 15, 2026
EPS Beat/Miss
+41.7%
Price Before
$3.88
Price After
$3.96
Q3 FY2025-12.77%
Report Date
Sep 29, 2025
EPS Beat/Miss
-34.5%
Price Before
$17.85
Price After
$15.57
Q2 FY2025-61.62%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$21.00
Price After
$8.06
Q2 FY2025-61.62%
Report Date
May 15, 2025
EPS Beat/Miss
+47.8%
Price Before
$21.00
Price After
$8.06
Q4 FY2024-11.70%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$79.50
Price After
$70.20
Q3 FY2024-1.49%
Report Date
Sep 30, 2024
EPS Beat/Miss
+48.7%
Price Before
$60.60
Price After
$59.70
Q2 FY2024-5.23%
Report Date
May 15, 2024
EPS Beat/Miss
—
Price Before
$91.80
Price After
$87.00
Avg Beat Reaction-14.75%
Avg Miss Reaction-12.77%
Beat Rate4 / 8 quarters
Largest Move-61.62% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IXHL ends December
Incannex Healthcare Limited (IXHL) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.35 — beating the analyst consensus of $-0.60 by +41.7%. IXHL has beaten EPS estimates for 2 consecutive quarters. The next IXHL earnings date is expected around September 1, 2026.
Each quarter, investors track IXHL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IXHL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IXHL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IXHL earnings · 5 questionsIncannex Healthcare Limited's next earnings report is expected around September 1, 2026. IXHL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IXHL historically reports after market close (AMC).
IXHL earnings datewhen is IXHL earningsIXHL next earnings datewhen does IXHL report earningsIXHL earnings calendar
▸ Source: FMP · Incannex Healthcare Limited SEC filings · US GAAP · Incannex Healthcare Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026